JP2025509510A5 - - Google Patents

Info

Publication number
JP2025509510A5
JP2025509510A5 JP2024554636A JP2024554636A JP2025509510A5 JP 2025509510 A5 JP2025509510 A5 JP 2025509510A5 JP 2024554636 A JP2024554636 A JP 2024554636A JP 2024554636 A JP2024554636 A JP 2024554636A JP 2025509510 A5 JP2025509510 A5 JP 2025509510A5
Authority
JP
Japan
Application number
JP2024554636A
Other languages
Japanese (ja)
Other versions
JP2025509510A (ja
JPWO2023178019A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064143 external-priority patent/WO2023178019A1/en
Publication of JP2025509510A publication Critical patent/JP2025509510A/ja
Publication of JPWO2023178019A5 publication Critical patent/JPWO2023178019A5/ja
Publication of JP2025509510A5 publication Critical patent/JP2025509510A5/ja
Pending legal-status Critical Current

Links

JP2024554636A 2022-03-14 2023-03-10 乳がんのための併用療法 Pending JP2025509510A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269326P 2022-03-14 2022-03-14
US63/269,326 2022-03-14
PCT/US2023/064143 WO2023178019A1 (en) 2022-03-14 2023-03-10 Combination therapies for breast cancer

Publications (3)

Publication Number Publication Date
JP2025509510A JP2025509510A (ja) 2025-04-11
JPWO2023178019A5 JPWO2023178019A5 (https=) 2026-03-10
JP2025509510A5 true JP2025509510A5 (https=) 2026-03-10

Family

ID=85937455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554636A Pending JP2025509510A (ja) 2022-03-14 2023-03-10 乳がんのための併用療法

Country Status (11)

Country Link
US (1) US20250177364A1 (https=)
EP (1) EP4493180A1 (https=)
JP (1) JP2025509510A (https=)
KR (1) KR20240163084A (https=)
CN (1) CN118843461A (https=)
AU (1) AU2023234511A1 (https=)
CA (1) CA3254271A1 (https=)
IL (1) IL315153A (https=)
MX (1) MX2024011183A (https=)
TW (1) TW202400230A (https=)
WO (1) WO2023178019A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2437300A (en) 1999-01-15 2000-08-01 Infineum International Ltd Improved fuel compositions
SG11201905622VA (en) 2017-01-17 2019-08-27 Genentech Inc Subcutaneous her2 antibody formulations
TWI800827B (zh) * 2020-05-12 2023-05-01 美商建南德克公司 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
MX2023000622A (es) 2020-07-14 2023-02-22 Genentech Inc Ensayos para combinaciones de dosis fija.

Similar Documents

Publication Publication Date Title
JP2025509510A5 (https=)
CL2025003710S1 (es) Cierre para una estructura de rampas para maniobras vehiculares.
CL2025003573A1 (es) Sistemas y métodos para la extracción de litio a partir de materias primas acuosas
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BY13151U (https=)
CN307046821S (https=)
BY13169U (https=)
BY13163U (https=)
BY13153U (https=)
BY13164U (https=)
BY13155U (https=)
BY13150U (https=)
BY13149U (https=)
CN307049876S (https=)
CN307048196S (https=)
CN307048039S (https=)
CN307047635S (https=)
BY13145U (https=)
CN307047423S (https=)